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BACKGROUND: Women at high ovarian cancer risk, especially those with mutations in BRCA1/BRCA2, are encouraged to undergo
bilateral risk-reducing salpingo-oophorectomy (BRRSPO) prior to the natural menopause. The decision to use HRT to cover the
period of oestrogen deprivation up to 50 years of age is difficult because of balancing the considerations of breast cancer risk, bone
and cardiovascular health.
METHODS: We reviewed by questionnaire 289 women after BRRSPO aged p48 years because of high ovarian cancer risk; 212 (73%)
of women responded.
RESULTS: Previous HRT users (n¼67) had significantly worse endocrine symptom scores than 67 current users (P¼0.006). A total
of 123 (58%) of women had X24 months of oestrogen deprivation o50 years with 78 (37%) never taking HRT. Bone density
(DXA) evaluations were available on 119 (56%) women: bone loss with a T score of p 1.0 was present in 5 out of 31 (16%)
women with no period of oestrogen deprivation o50 years compared with 37 out of 78 (47%) of those with X24 months
of oestrogen deprivation (P¼0.03).
INTERPRETATION: Women undergoing BRRSPO o50 years should be counselled concerning the risks/benefits of HRT, taking into
consideration the benefits on symptoms, bone health and cardiovascular health, and that the risks of breast cancer from oestrogen-
only HRT appear to be relatively small.
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Ovarian cancer is the fifth most common cause of cancer mortality
in Western women and causes more deaths than all other cancers
of the reproductive organs combined (Morrison et al, 2002).
Approximately 8–15% of ovarian cancers are thought to be caused
by inheritance of germline mutations in high-risk cancer-predis-
posing genes, such as BRCA1 and BRCA2 (Schildkraut and
Thompson, 1988; Whittemore et al, 1997; Risch et al, 2001;
Antoniou et al, 2003). The risk of ovarian cancer by age 70 in
BRCA1 mutation carriers is between 39–63%, and 11–30%
for BRCA2 carriers (Antoniou et al, 2003; Evans et al, 2008).
Approximately 75% of women present with stage III/IV cancer,
and 5-year survival for women presenting at stage IV is o5%
(Teneriello and Park, 1995). The efficacy of screening methods,
which include pelvic examination, transvaginal ultrasound and
serum CA125 analysis, remains to be proven (Oei et al, 2006;
Hermsen et al, 2007; Evans et al, 2009a,b). Bilateral risk-reducing
salpingo-oophorectomy (BRRSPO) is, therefore, often undertaken,
and has been shown to reduce the risk of ovarian cancer by 96%
and breast cancer by 53% (Rebbeck et al, 2002).
While reducing cancer risk, BRRSPO is not without conse-
quences, particularly those relating to oestrogen deprivation from
surgically induced menopause. These include symptoms of
oestrogen deprivation, including hot and cold flushes, gastro-
intestinal problems, alterations in mood and sexual dysfunction
(Elit et al, 2001; Madalinska et al, 2005; Gallicchio et al, 2006).
Oestrogen deprivation also leads to loss of bone mineral density
(BMD) and risk of osteoporosis and bone fracture (Jones et al,
1985; Cummings et al, 1998), and may shorten lifespan related to
earlier onset cardiovascular disease (Howell and Evans, 2011).
The greatest rate of BMD loss occurs soon after oophorectomy,
and is reported to be as high as 20% in the first 18 months (Cann
et al, 1980). The rate of bone loss reduces with time, but early
menopause is a risk factor for fractures much later in life (van der
Voort et al, 2003).
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sHormone replacement therapy reduces symptoms associated
with menopause in some women, and protects against bone
density loss. However, HRT, particularly combined oestrogen and
progesterone preparations, increases breast cancer risk and use
is relatively contraindicated in women with or at high risk of
breast cancer, although, paradoxically, recent observational data
indicate that HRT use does not increase risk of breast cancer
after BRRSPO in BRCA1 and possibly not BRCA2 carriers
(Anderson et al, 2003; Collaborators MWS, 2003; Rebbeck et al,
2005). Oestrogen-only HRT did not increase breast cancer risk in
older women in the general population in the Women’s Health
Initiative (WHI) randomised trial (Anderson et al, 2003), and
observational data from Denmark (Ewertz et al, 2005) indicates
that it does not increase risk of breast cancer in women under 50
years. Based on these data, we and others offer HRT to carriers
after surgery.
In this study, we investigated the uptake of HRT after BRRSPO
and assessed menopausal symptoms and the use of, and results of,
DXA scans used to monitor bone density in this population
women.
MATERIALS AND METHODS
Study participants
Women were identified from our BRCA1/2 database and a further
database of patients at increased familial risk of ovarian cancer.
Mutation carriers or other women with at least a 10% lifetime risk
of ovarian cancer due to family history of ovarian ± breast cancer
or Lynch syndrome and who had undergone BRRSPO were
eligible. Women with BRRSPO 448 years were excluded, because
of the potentially short period of oestrogen deprivation before a
natural menopause. Women were sent a questionnaire and
provided with pre-paid envelope for its return.
Measures
The questionnaire enquired about ever or previous use of HRT,
menopausal symptoms and whether DXA scans had been per-
formed and their results.
The 18-item functional assessment of cancer therapy-endocrine
symptoms (FACT-ES) questionnaire was used to assess menopau-
sal symptoms. This has been shown to have acceptable validity
and reliability for use in trials of endocrine therapy (Fallowfield
et al, 1999). Women were asked to report occurrence of symptoms
in the last 7 days, which were scored on a five-point Likert-type
scale, ranging from ‘not at all’ to ‘very much’. These scores could
then be reversed and summed to obtain a ‘total endocrine score’,
ranging from 0 to 72, with lower values, indicating worse
symptoms.
Statistical analysis
Descriptive statistics were used to characterise basic demographic
and medical information, and to determine HRT patterns of use
and DXA scan information. The statistical package SPSSX version
16.0 (IBM Corporation, Armonk, NY, USA) was used for analysis.
Although endocrine symptom data were negatively skewed,
parametric tests were used to retain the score interpretability, as
these are fairly robust on skewed data, between ‘never users’,
‘previous users’ and ‘current users’, and the answers to specific
questions on the FACT-ES questionnaire and also between patients
who were grouped into three time intervals for bone density
comparison: ‘0’, ‘1–23’ and ‘X24 months’. In addition, Kruskal–
Wallis and Mann–Whitney non-parametric tests were used for
three and two group combinations to determine the relationship
between the total FACT-ES score. All tests were two sided and
a¼0.05.
Ethical approval
All research components of this study were performed with ethical
approval of the Central Manchester Research Ethics committee.
DXA scanning
Scans (DXA) were offered to all women who joined the study,
although this was aimed primarily at those with bone unprotected
by oestrogen prior to 50 years of age. The DXA was performed on a
Hologic Discovery A DXA scanner with Apex System Software
Version 2.3.2 software (Apex Systems, Hermitage, Berkshire, UK).
Classification was undertaken using WHO criteria based on age-
matched controls (WHO report, 1994). A T score in the lumbar
vertebrae (L1–L4) or left neck of femur (hip) 4 1.0 was
considered normal; scores of  1.0 to  2.4 were considered as
osteopenic and p 2.5, osteoporotic.
RESULTS
Demographics and medical information of participants
We identified 385 women who had undergone BRRSPO from the
Manchester Genetic Medicine Department Filemaker Pro data-
bases. Five of these were found to have died at the time of the
study, and 91 were excluded on the basis of age at oophorectomy.
Two hundred and eighty-nine (163 from BRCA1/2 mutation
positive families) women were sent questionnaire packs, and 212
of these responded, giving a response rate of 73%. The patient
characteristics of responders is provided in Table 1. Response rates
among BRCA1/2 families were a little higher: 123 out of 163 (75%)
than for those from families not proven to be BRCA1/2: 89 out of
126 (71%). The median age of responders was 50 years (age range,
36–77). The median age at oophorectomy was 41 years (range,
24–48 years). Seventy-six per cent of women had hysterectomy at
the time of BRRSPO, 24% had a BRRSPO only (Figure 1).
HRT use
Women could be divided into never users of HRT (78 out of 212,
37%) and women who had taken HRT at some point (134 out of
212, 63%). In all, 87 women used HRT immediately after BRRSPO
and 47 had a delay of up to 2 years before starting HRT. Of the
patients receiving HRT, 67 out of 134 (50%) were current users at
the time of completing the questionnaires and 67 (50%) were
previous users (Figure 1; Tables 1 and 2). The majority used
oestrogen-only preparations (79%). Only 7% used combination
oestrogen and progesterone therapies, and 14% used other
preparations, such as tibolone (n¼12) and raloxifene (n¼2).
This use reflects that the majority of women had hysterectomy and
BSO. The mean time of HRT use was 3.4 years (0.1–19 years).
In all, 123 out of 212 (58%) women spent X24 months before the
Table 1 Patient characteristics of 212 women returning questionnaires
Immediate
HRT (I)
Delayed
HRT (D)
No
HRT (N) Total
Number 87 (%) 47 (%) 78 (%) 212 (%)
Age at surgery
median (range)
41.7 (24–48) 40.4 (27.5–48) 41.4 (31–48) 41.2 (24–48)
BRCA1/2 family 44 (51) 30 (64) 49 (63) 123 (58)
Family history of
ovary/breast cancer
42 (49) 17 (46) 29 (37) 88 (42)
Current users 43 (50) 24 (46) — 67 (32)
Previous users 44 (51) 23 (48) — 67 (32)
X24 months
no HRT o50 years
27 (31) 24 (51) 72 123 (58)
Abbreviation: HRT¼hormone replacement therapy.
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sage of 50 not taking HRT, resulting in a significant amount of time
without oestrogen protection.
Most women (153 out of 212 (72%)) remember discussing the
pros and cons of taking HRT with a health professional before
treatment (8 were uncertain) and most (22 out of 37 (60%)) of
those who did not discuss the issues wished that they had (12 did
not answer the question). Women were asked why they chose not
to use HRT and 56 out of 78 (72%) cited about breast cancer risk.
Menopausal symptoms
Since the questionnaire was completed at different times after
oophorectomy ranging from months to 36 years, and at differing
ages, there were limitations to the interpretation of these scores.
Women were divided into three groups for statistical analysis:
those who had never used HRT (N), those who had previously used
HRT but were not currently taking it (P) and those who were
currently taking HRT (C). Of group (P), 44 out of 67 (66%) started
HRT immediately after their BRRSPO. Results of covariate
analysis were age when questionnaire completed (P¼0.096),
BRCA mutation (P¼0.051) and HRT group (P¼0.017). Six
patients, two in each group, did not complete the FACT-ES forms.
Although age did not appear to be a significant covariant, it was
divided into 10-year groups (Table 2), a greater percentage of
patients in the 40–49 age group had a total score o50 (the lower
quartile of all groups), particularly in the past users (P) group.
Using independent sample t-tests to compare the means, there
was a significant differences in total scores between all three
groups analysed (N), (P) and (C) (P¼0.017) This significant
difference was largely explained by the difference between (P) and
(C) (P¼0.006) (Table 3). When split into 10-year age groups, the
difference between these two HRT groups was largely explained by
the age group 40–49 years (P¼0.001). Current users (C) had a
mean score of 58.7 compared with 53 for previous users (P). The
65 (P) had been off HRT for 0.2–11 (median 3.7) years, whereas
never users were subject to oestrogen deprivation from BRRSPO
for 0.5–29 years (median 5.2). The inter-group differences (N)
(mean score 55.6) and (P) was neither significant (P¼0.180) nor
was it significant between (N) and (C) (P¼0.093). There were no
significant differences found when the other inter-group differ-
ences were compared.
In order to address a possible difference between women who
delayed HRT use (D) and women who immediately took HRT (I),
we assessed their total endocrine scores. There was no difference in
total endocrine scores between group (I) (mean 56.7) and group
(D) (median 55.5). Similarly, the proportions with scores of o50
between (I) and (D) was similar (26%; 22%). The proportion of
women who had never used HRT (N) with scores of o50 was 20%.
Those questions, where at least 20% of all HRT groups answered
‘very much’ or ‘quite a bit’, are shown in Table 4 by HRT group.
The percentage of patients currently on HRT treatment (C)
experiencing ‘very much’ or ‘quite a bit’ appears to be less for hot
flushes, night sweats and vaginal dryness.
Scores of o50 persisted up to 65 years of age and was generally
more common in each age cohort among previous users (P)
(Table 2).
Bone protection
Our recently introduced guidelines indicate that after BRRSPO,
women should have bone DXA scans every 2–5 years, if not taking
Table 2 Age at current assessment and substantial endocrine symptoms
by FACT-ES in 206 women returning questionnaires
Age at assessment N HRT group n Scoreo50
30–39 12 N 4 (33%) 1 (25%)
P 3 (25%) —
C 5 (42%) 1 (20%)
40–49 95 N 33 (35%) 9 (27%)
P 22 (23%) 11 (50%)
C 40 (42%) 6 (15%)
50–59 77 N 31 (40%) 7 (23%)
P 28 (36%) 8 (29%)
C 18 (24%) 5 (28%)
60+ 22 N 8 (36%) 3 (38%)
P 12 (55%) 1 (8%)
C 2 (9%) —
Abbreviations: C¼current users; FACT-ES¼functional assessment of cancer
therapy-endocrine symptoms; HRT¼hormone replacement therapy; N¼never
users; P¼past users.
385 Women at high risk of
breast/ovarian cancer
who have undergone
BRRSPO
380 Women
289 Women eligible for
study
47 Delayed
HRT use
212 (73%) BRRSPO eligible
women returned questionnaire
5 Patients died
70 (24%) BRRSPO only
219 (76%) hysterectomy
plus BRRSPO
125 No immediate HRT use
77 Patients no response
to questionnaire
87 Immediate HRT
91 Underwent BRRSPO
>48 years of age
78 (37%)
Never HRT
43 Current
HRT
44 No current
HRT
23 No current
HRT use
24 Current
HRT use
163 BRCA1/2 carriers
134 (63%) HRT use
Figure 1 Flow diagram for BRRSPO cases.
Table 3 Comparison of total endocrine scores between HRT groups
Length of oestrogen
deprivation N
a Mean score
b s.d. t-value DF P-value
N vs P vs C 76 55.6 10.8 4.18 205 0.017
65 53.0 12.0
65 58.7 11.0
N vs P 1.35 139 0.180
N vs C  1.69 139 0.093
P vs C  2.82 128 0.006
Age group 40–49 years
N vs P vs C 33 56.2 10.5 6.25 94 0.003
22 48.9 10.2
40 59.0 11.4
P vs C  3.46 60 0.001
Abbreviations: C¼current users; DF¼degrees of freedom; FACT-ES¼functional
assessment of cancer therapy-endocrine symptoms; HRT¼hormone replacement
therapy; N¼never users; P¼past users.
aTwo from each group did not complete
FACT-ES form.
bScores are reversed, that is, max 72 equates to no symptoms.
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sHRT under 50 years of age. The mean period of non-HRT use
among 139 women who were without oestrogen protection at some
stage before age 50 was 5.2 years (range 1–19 years; median
5 years). One hundred and twenty-three women had at least 2 years
of oestrogen deprivation before 50 years. In this retrospective
study, only 73 out of 210 (36%) of women had a DEXA scan during
an average period of risk o50 years of age of 6.33 years. According
to the questionnaires, only 48 of 123 with X24 months of
oestrogen deprivation had undergone a DXA scan (40%; scan
findings were unavailable on six).
Scans have now been arranged on 119 women (Table 5). Of
those who have now had a scan, 38% (45 out of 119) were found to
have abnormal results. Based on the most recent DXA reports,
33 out of 119 (28%) reported reduced bone mass consistent with
osteopenia and 12 out of 119 (10%) indicated osteoporosis. The
prevalence of reduced bone mass was far higher among women
who had X24 months of oestrogen deprivation (36 out of 78
(46%)) than in those who had taken HRT to cover any period o50
years of age (5 out of 31 (16%)). The w
2 analysis of HRT groups
and DXA results shows a significant difference between those with
X24 months of oestrogen deprivation and those with no
deprivation o50 years (P¼0.03). Of those who had not been
scanned prior to the study who had X24 months of oestrogen
deprivation, 67 out of 71 (95%) wished to be scanned. However,
24 wished for their scans to be organised by their general
practitioners and eight had not attended, thus results were only
available on an additional 35 women.
DISCUSSION
To our knowledge, this is the only study to address the issues of
HRT use, and both endocrine symptoms and bone health among
women choosing BRRSPO because of an elevated risk of ovarian
cancer. Madalinska et al (2005) did report on significant endocrine
symptoms in women who had undergone BRRSPO for the same
reason. In addition to the importance of adequate bone protection,
BRRSPO puts women at risk of experiencing the symptoms of
menopause from an early age. One way to combat both of these
problems is to use HRT. This decision is not straightforward,
however, especially in women with BRCA1/2 mutations, because of
the established links between HRT and breast cancer. Currently,
there are no accepted guidelines on HRT use in this cohort of
patients, although it has been suggested that it is acceptable for a
short period of time in women who are experiencing symptoms
(Armstrong et al, 2004; Rebbeck et al, 2005). Indeed, the reported
lack of increase in breast cancer risk from HRT use after early
BRRSPO (Rebbeck et al, 2005) suggests that the risk benefit ratio is
in favour of use up until 50 years of age. Even a small abrogation of
the protective effect of BRRSPO would be counterbalanced by the
favourable effects of HRT on bone health and cardiovascular risks,
mental health and the incidence of Parkinsonism when used at age
o50 years (Anderson et al, 2003; Armstrong et al, 2004; Rivera
et al, 2009; Rocca et al, 2009; Shuster et al, 2010) Once the
immediate and long-term morbidity and mortality risks from bone
density loss and heart disease are included, life expectancy is likely
to be increased by HRT use up to 50 years of age (Armstrong et al,
2004; Rebbeck et al, 2005; Rivera et al, 2009; Salpeter et al, 2009;
Howell and Evans, 2011).
We collected data on symptoms only at the time women filled in
the questionnaire. Surprisingly, at this time, the women who were
having the most severe symptoms (hot flushes, cold and night
sweats and vaginal discharge) were previous users of HRT. This
may be because of the knowledge of effectiveness while taking
HRT. Never users would not have this experience of alleviation of
symptoms and thus may perceive symptoms to be less severe.
Our study suggests that for some women stopping HRT it may be
difficult, since they are more aware of the benefits. In all, 65% of
these women commenced HRT immediately, which means that
only 35% would have initiated HRT use potentially due to bad
menopausal symptoms. Importantly, this group who delayed
commencement of HRT did not have significantly higher
endocrine scores than those who started immediately after
BRRSPO. Equally, the group who have never taken HRT may
have had few symptoms and only those with the severest
symptoms would choose to take HRT and thus end up in one of
the other two groups. However, if this was the case, we might have
expected worse endocrine symptoms among those women who
had delayed HRT usage. There was no evidence of this with similar
proportions of ‘immediate’ and ‘delayed’ use women having high
endocrine scores and with similar mean and median scores. This
was further supported by similar proportions of never users
having severe symptoms to current users. This current study
suggests that for some women taking HRT, it may more difficult to
stop usage later, as they are aware of the benefits on their
symptoms unlike those who have never taken HRT.
The risk of breast cancer in this cohort of women appears to be
the main cause of concern about taking HRT. For many women,
their decision making will have been before evidence that HRT
does not appear to abrogate the protective effect of BRRSPO
(Rebbeck et al, 2005), and the WHI randomised trial of oestrogen-
only use showing reduction in breast cancer risk with oestrogen-
only use, albeit in women aged 50–59 (Anderson et al, 2003;
LaCroix et al, 2011). It is not clear why the largest observational
trial, the Million Women Study, shows completely the opposite
Table 4 Individual questions where X20% of all patients experienced a
symptom ‘very much’ or ‘quite a bit’
Endocrine symptom
Experiencing ‘very much’ or
‘quite a bit’ (%)
HRT group All N P C
Lost interest in sex 34 39 30 31
Gained weight 32 28 39 31
Hot flushes 24 25 32 15
Night sweats 23 26 33 9
Vaginal dryness 23 25 31 14
Feel bloated 20 13 28 22
Abbreviations: C¼current users; HRT¼hormone replacement therapy; N¼never
users; P¼past users.
Table 5 Prevalence of osteopenia and osteoporosis in 119 women undergoing risk-reducing oophorectomy aged 48 years or younger
Length of oestrogen
deprivation
Median age at
BRRSPO (range)
Median age at
DXA (range)
DXA
normal
Osteopenia
(DXA T score  1.0 to  2.4)
Osteoporosis
(DXA T score o 2.4)
0 42.6 (31–48) 49 (41–61) 26 (84%) 4 (13%) 1 (3%)
1–23 months 42.9 (34–48) 50 (32–68) 6 (60%) 3 (30%) 1 (10%)
X24 months 41.1 (24.9–48) 50 (38–78) 42 (54%) 26 (33%) 10 (13%)
Abbreviation: BRRSPO¼bilateral risk-reducing salpingo-oophorectomy. Difference between no oestrogen deprivation group and X24 months group significant for reduced
bone density (osteopenia or osteoporosis), P¼0.03.
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our centre is not as high as might be expected and the false fear
of breast cancer risk being elevated against the concern about
menopausal symptoms and HRT use may still be having an effect
on uptake (Evans et al, 2009b). Our study showed that 77%
of women stopped HRT due to worries about breast cancer risk.
Counselling regarding the lack of evidence of breast cancer risk
due to HRT in this cohort of patients is essential, in addition to
highlighting the negative bone and cardiovascular effects of lack
of use. We feel that the data available support the use of HRT in
this population of women.
The BRCA1/2 mutation carriers are recommended to undergo
BRRSPO after the age of 35 years, or when childbearing is complete
(Armstrong et al, 2004) In this retrospective study, we found that
59% (125 out of 212) women with early menopause due to BRRSPO
chose not to have HRT after surgery, although 47 (22%)
subsequently took HRT. Of those that did elect to take HRT at
some stage, 134 women (63%) were on treatment for a mean of
3.4 years. A total of 133 women were without oestrogen protection
at some stage o50, with 123 (58%) having at least 2 years
oestrogen deprivation. Despite this, only 40% (48 out of 119) of
women with significant oestrogen deprivation had been offered a
DXA scan. Our study indicated that only 36% of women had ever
had a DXA, and, of these, it was noted that 30% had osteopenia
and 10% osteoporosis. Among women with X24 months of
oestrogen deprivation, 46% of women were osteopenic or
osteoporotic. These data support those of Tham et al (2006),
who reported that only 32% of women with chemotherapy-induced
menopause had testing for BMD loss and for most this issue was
not even discussed. Our study showed that most women (76%)
wished to be scanned or to have their scans repeated and this rose
to 95% of those with X24 months of oestrogen deprivation.
Currently, no single health-care provider appears to be taking
control of bone health in this group of women. Hormone
replacement therapy may be started by the gynaecologist, but
later the woman or her general practitioner may stop HRT before
the natural menopause age (B50 years). It is important, therefore,
to not only impress upon health-care providers the importance of
DXA scanning in this group of patients, but to ask them to discuss
it with women and relate to them current guidelines. Data indicate
that the greatest proportion of BMD loss occurs in the first
18 months following surgery, after which the rate of loss begins to
decrease (Cann et al, 1980). It may, therefore, be useful to amend
the current guidelines to assess BMD at the time of surgery or
before surgery for a baseline measurement, scan again at 1 or 2
years to detect any rapid BMD loss that may need treatment,
and then again at 2 years before switching to every 5 years once the
rate of loss has slowed.
This study has several limitations, including the retrospective
nature. We relied on the woman’s own memory of HRT usage
and there are likely to be errors regarding duration of HRT. We do
not know the reasons for starting/stopping medication. However,
it is likely that women’s knowledge of never or continual use is
accurate. The response rate to the questionnaire of 73% is good,
but it is possible that women with greater concerns about bone
health may have responded disproportionately. Clearly, a
prospective study would inform further regarding issues of bone
and other health issues in women undergoing early BRRSPO.
We have demonstrated that endocrine symptoms are signifi-
cantly more severe in previous users of HRT compared
with current users and there is a high rate of bone loss in
women who have X24 months of oestrogen deprivation prior to
50 years of age. Thus women should be encouraged to take
continuous HRT for better control of symptoms after BRRSPO
at least until they reach 50 years and counselled concerning the
pros and cons of this advice (Howell and Evans, 2011).
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